Clinical Trial Update: Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib combined with liposomal doxorubicin, dexamethasone, and cyclophosphamide in multiple myeloma that relapsed after autologous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Doxil (liposomal doxorubicin)
• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2015-01-12